BioCentury | Apr 20, 2009
Clinical News

Diadep: Pilot trial started

...first time with Copegus ribavirin and Pegasys pegylated interferon alfa-2a from Roche (SIX:ROG, Basel, Switzerland). Biocortech S.A.S....
BioCentury | Dec 11, 2006
Company News

Biocortech, Servier deal

...Biocortech partnered to discover and develop compounds to treat neuropsychiatric disorders. Under the three-year deal, Biocortech...
...will provide undisclosed targets and Servier will be responsible for development, regulatory work and commercialization. Biocortech...
...be eligible for milestones and royalties. Servier will have exclusive worldwide rights to resulting compounds. Biocortech S.A.S....
BioCentury | Feb 27, 2006
Company News

Biocortech SAS, Columbia University deal

...Biocortech's technology for generating editing profiles of the receptor with the university's CNS tissue collection. Biocortech...
Items per page:
1 - 3 of 3
BioCentury | Apr 20, 2009
Clinical News

Diadep: Pilot trial started

...first time with Copegus ribavirin and Pegasys pegylated interferon alfa-2a from Roche (SIX:ROG, Basel, Switzerland). Biocortech S.A.S....
BioCentury | Dec 11, 2006
Company News

Biocortech, Servier deal

...Biocortech partnered to discover and develop compounds to treat neuropsychiatric disorders. Under the three-year deal, Biocortech...
...will provide undisclosed targets and Servier will be responsible for development, regulatory work and commercialization. Biocortech...
...be eligible for milestones and royalties. Servier will have exclusive worldwide rights to resulting compounds. Biocortech S.A.S....
BioCentury | Feb 27, 2006
Company News

Biocortech SAS, Columbia University deal

...Biocortech's technology for generating editing profiles of the receptor with the university's CNS tissue collection. Biocortech...
Items per page:
1 - 3 of 3